Home LiteratureArticle Details
PMID: 28575312 Published · ppublish English Journal Article Review

The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.

Neuro-oncology ·Vol. 19 ·No. 11 ·2017-10-19 ·Pages 1435-1446

Zhu C, Kros JM, Cheng C, Mustafa D

Abstract

"Tumor-associated macrophages" (TAMs) form a significant cell population in malignant tumors and contribute to tumor growth, metastasis, and neovascularization. Gliomas are characterized by extensive neo-angiogenesis, and knowledge of the role of TAMs in neovascularization is important for future anti-angiogenic therapies. The phenotypes and functions of TAMs are heterogeneous and more complex than a classification into M1 and M2 inflammation response types would suggest. In this review, we provide an update on the current knowledge of the ontogeny of TAMs, focusing on diffuse gliomas. The role of TAMs in the regulation of the different processes in tumor angiogenesis is highlighted and the most recently discovered mechanisms by which TAMs mediate resistance against current antivascular therapies are mentioned. Novel compounds tested in clinical trials are discussed and brought in relation to different TAM-related angiogenesis pathways. In addition, potential therapeutic targets used to intervene in TAM-regulated tumor angiogenesis are summarized.

Keywords
angiogenesis glioma therapy tumor-associated macrophages
MeSH Terms
Animals Glioma/immunology,therapy Humans Immunotherapy Macrophages/immunology Neovascularization, Pathologic/immunology Tumor Microenvironment/immunology
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Zhu Changbin
Department of Pathology, Division of Experimental Cardiology, Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands; Department of Nephrology and Hypertension, DIGD, University Medical Center Utrecht, Utrecht, Netherlands.
Kros Johan M
Department of Pathology, Division of Experimental Cardiology, Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands; Department of Nephrology and Hypertension, DIGD, University Medical Center Utrecht, Utrecht, Netherlands.
Cheng Caroline
Department of Pathology, Division of Experimental Cardiology, Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands; Department of Nephrology and Hypertension, DIGD, University Medical Center Utrecht, Utrecht, Netherlands.
Mustafa Dana
Department of Pathology, Division of Experimental Cardiology, Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands; Department of Nephrology and Hypertension, DIGD, University Medical Center Utrecht, Utrecht, Netherlands.
References (115)
115 references, click to expand
  1. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells.
    Oncoimmunology. 2013 Dec 1;2(12):e26968 PMID: 24498562
  2. The role of IL-1β in the early tumor cell-induced angiogenic response.
    J Immunol. 2013 Apr 1;190(7):3500-9 PMID: 23475218
  3. Glioblastoma-derived Macrophage Colony-stimulating Factor (MCSF) Induces Microglial Release of Insulin-like Growth Factor-binding Protein 1 (IGFBP1) to Promote Angiogenesis.
    J Biol Chem. 2015 Sep 18;290(38):23401-15 PMID: 26245897
  4. Flt-1 signaling in macrophages promotes glioma growth in vivo.
    Cancer Res. 2008 Sep 15;68(18):7342-51 PMID: 18794121
  5. Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation.
    Oncotarget. 2016 Dec 20;7(51):83976-83986 PMID: 27824617
  6. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling.
    Nat Cell Biol. 2011 Sep 11;13(10):1202-13 PMID: 21909098
  7. Hypoxia and tumor-associated macrophages: A deadly alliance in support of tumor progression.
    Oncoimmunology. 2014 Jan 1;3(1):e27561 PMID: 24744977
  8. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse.
    Int J Cancer. 2014 Jan 1;134(1):32-42 PMID: 23784932
  9. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity.
    Cancer Cell. 2013 Dec 9;24(6):695-709 PMID: 24332039
  10. Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2.
    Cancer Res. 2007 Sep 15;67(18):8429-32 PMID: 17875679
  11. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.
    Cancer Res. 2012 Mar 1;72(5):1103-15 PMID: 22237627
  12. Epidermal growth factor receptor inhibition by erlotinib prevents vascular smooth muscle cell and monocyte-macrophage function in vitro.
    Transpl Immunol. 2015 Jun;32(3):175-8 PMID: 25791345
  13. Purification of guinea pig YKL40 and modulation of its secretion by cultured articular chondrocytes.
    J Cell Biochem. 1998 Jun 15;69(4):414-24 PMID: 9620168
  14. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
    Eur J Cancer. 2010 Jul;46(11):2010-9 PMID: 20621734
  15. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.
    Neuro Oncol. 2013 Aug;15(8):1079-87 PMID: 23828240
  16. Vascular-resident CD169-positive monocytes and macrophages control neutrophil accumulation in the kidney with ischemia-reperfusion injury.
    J Am Soc Nephrol. 2015 Apr;26(4):896-906 PMID: 25266072
  17. Tumor-associated macrophages: functional diversity, clinical significance, and open questions.
    Semin Immunopathol. 2013 Sep;35(5):585-600 PMID: 23657835
  18. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade.
    Cell Rep. 2014 Aug 7;8(3):696-706 PMID: 25088418
  19. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.
    JCI Insight. 2016;1(2):null PMID: 26973881
  20. Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis.
    Blood. 2009 Feb 26;113(9):1992-2002 PMID: 19060246
  21. The great escape; the hallmarks of resistance to antiangiogenic therapy.
    Pharmacol Rev. 2015;67(2):441-61 PMID: 25769965
  22. Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer.
    Cancer Res. 2014 Jun 1;74(11):2962-73 PMID: 24638982
  23. Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions.
    Cardiovasc Res. 2001 Feb 16;49(3):671-80 PMID: 11166280
  24. Semaphorin-3D and semaphorin-3E inhibit the development of tumors from glioblastoma cells implanted in the cortex of the brain.
    PLoS One. 2012;7(8):e42912 PMID: 22936999
  25. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
    Cancer Res. 2011 Sep 15;71(18):6073-83 PMID: 21803743
  26. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo.
    Blood. 2002 Dec 15;100(13):4622-8 PMID: 12453880
  27. Macrophages and endothelial cells orchestrate tumor-associated angiogenesis in oral cancer via hedgehog pathway activation.
    Tumour Biol. 2016 Jul;37(7):9233-41 PMID: 26768620
  28. A two-way communication between microglial cells and angiogenic sprouts regulates angiogenesis in aortic ring cultures.
    PLoS One. 2011 Jan 10;6(1):e15846 PMID: 21264342
  29. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages.
    J Exp Med. 2008 Jul 7;205(7):1673-85 PMID: 18559453
  30. The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.
    Biochem J. 2015 Jan 15;465(2):271-9 PMID: 25351958
  31. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes.
    Cancer Res. 2010 Jul 15;70(14):5728-39 PMID: 20570887
  32. Sorafenib induces autophagy and suppresses activation of human macrophage.
    Int Immunopharmacol. 2013 Feb;15(2):333-9 PMID: 23337882
  33. VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment.
    Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):658-64 PMID: 18174461
  34. Phagocyte-myocyte interactions and consequences during hypoxic wound healing.
    Cell Immunol. 2014 Sep-Oct;291(1-2):65-73 PMID: 24862542
  35. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes.
    Oncotarget. 2014 Apr 30;5(8):2208-20 PMID: 24809734
  36. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.
    Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3501-6 PMID: 23382202
  37. Polarized CD163+ tumor-associated macrophages are associated with increased angiogenesis and CXCL12 expression in gastric cancer.
    Clin Res Hepatol Gastroenterol. 2016 Jun;40(3):357-365 PMID: 26508473
  38. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.
    Oncogene. 2008 Jan 24;27(5):663-74 PMID: 17667938
  39. Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site.
    Immunobiology. 2011 Nov;216(11):1192-202 PMID: 21803441
  40. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
    Oncogene. 2017 Jun 29;36(26):3749-3759 PMID: 28218903
  41. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.
    Cancer Res. 2013 Feb 1;73(3):1128-41 PMID: 23221383
  42. Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance.
    PLoS One. 2015 May 15;10(5):e0126022 PMID: 25978454
  43. KIT oncogene inhibition drives intratumoral macrophage M2 polarization.
    J Exp Med. 2013 Dec 16;210(13):2873-86 PMID: 24323358
  44. NRP1 acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis.
    Blood. 2013 Mar 21;121(12):2352-62 PMID: 23315162
  45. Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy.
    Cancer Res. 2015 Sep 1;75(17):3479-91 PMID: 26269531
  46. Microvascular density, CD68 and tryptase expression in human diffuse large B-cell lymphoma.
    Leuk Res. 2014 Nov;38(11):1374-7 PMID: 25293515
  47. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
    Neuro Oncol. 2016 Apr;18(4):557-64 PMID: 26449250
  48. Macrophages overexpressing VEGF, transdifferentiate into endothelial-like cells in vitro and in vivo.
    Biotechnol Lett. 2011 Sep;33(9):1751-8 PMID: 21626419
  49. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro.
    J Cereb Blood Flow Metab. 2008 Jan;28(1):90-8 PMID: 17519976
  50. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma.
    Oncotarget. 2012 Sep;3(9):1036-48 PMID: 23013619
  51. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population.
    Cancer Res. 2014 Jan 1;74(1):24-30 PMID: 24220244
  52. Tumor-derived mural-like cells coordinate with endothelial cells: role of YKL-40 in mural cell-mediated angiogenesis.
    Oncogene. 2014 Apr 17;33(16):2110-22 PMID: 23665676
  53. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
    Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4476-81 PMID: 27044098
  54. Heme oxygenase (HO)-1 expressing macrophages/microglial cells accumulate during oligodendroglioma progression.
    Brain Res. 2000 Nov 3;882(1-2):1-8 PMID: 11056178
  55. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Gut. 2017 Jan;66(1):157-167 PMID: 26452628
  56. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.
    Clin Cancer Res. 2011 Jul 15;17 (14 ):4872-81 PMID: 21632852
  57. IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia.
    Immunobiology. 2010 Sep-Oct;215(9-10):796-803 PMID: 20692534
  58. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice.
    J Clin Invest. 2011 May;121(5):1969-73 PMID: 21490397
  59. VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis.
    Cancer Res. 2013 Jul 15;73(14):4212-21 PMID: 23695550
  60. The role of macrophage phenotype in vascularization of tissue engineering scaffolds.
    Biomaterials. 2014 May;35(15):4477-88 PMID: 24589361
  61. The role of monocytes-macrophages in vasculogenesis in multiple myeloma.
    Leukemia. 2009 Sep;23(9):1535-6 PMID: 19738626
  62. Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells.
    Nature. 2011 May 29;474(7352):511-5 PMID: 21623369
  63. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.
    Neuro Oncol. 2016 Jun;18(6):797-806 PMID: 26538619
  64. Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1.
    PLoS One. 2015 Feb 06;10(2):e0116644 PMID: 25658639
  65. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
    Neuro Oncol. 2012 Nov;14 (11):1379-92 PMID: 22965162
  66. CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation.
    Immunity. 2016 Feb 16;44(2):303-15 PMID: 26885857
  67. Microglia and brain macrophages: An update.
    Neuropathology. 2017 Oct;37(5):452-464 PMID: 27859676
  68. The role of myeloid cells in the promotion of tumour angiogenesis.
    Nat Rev Cancer. 2008 Aug;8(8):618-31 PMID: 18633355
  69. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
    Hepatology. 2013 Jun;57(6):2358-68 PMID: 23424039
  70. M2-like tumor-associated macrophages drive vasculogenic mimicry through amplification of IL-6 expression in glioma cells.
    Oncotarget. 2017 Jan 3;8(1):819-832 PMID: 27903982
  71. Natural history of neurofibromatosis 1-associated optic nerve glioma in mice.
    Ann Neurol. 2005 Jan;57(1):119-27 PMID: 15622533
  72. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.
    Clin Cancer Res. 2014 Jun 15;20(12):3146-58 PMID: 24718867
  73. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors.
    Int J Cancer. 2010 Aug 15;127(4):899-909 PMID: 20013807
  74. The cellular and molecular origin of tumor-associated macrophages.
    Science. 2014 May 23;344(6186):921-5 PMID: 24812208
  75. A reappraisal of macrophage polarization in glioblastoma: Histopathological and immunohistochemical findings and review of the literature.
    Pathol Res Pract. 2016 Jun;212(6):491-9 PMID: 27101800
  76. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction.
    Blood. 2010 Aug 5;116(5):829-40 PMID: 20404134
  77. Cediranib for metastatic alveolar soft part sarcoma.
    J Clin Oncol. 2013 Jun 20;31(18):2296-302 PMID: 23630200
  78. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy.
    J Clin Invest. 2014 Feb;124(2):812-23 PMID: 24430180
  79. Macrophage regulation of tumor responses to anticancer therapies.
    Cancer Cell. 2013 Mar 18;23(3):277-86 PMID: 23518347
  80. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
    Br J Cancer. 2006 Jan 30;94(2):259-67 PMID: 16404427
  81. BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines.
    Br J Haematol. 2011 Nov;155(3):398-402 PMID: 21517818
  82. CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer.
    Oncotarget. 2015 Oct 27;6(33):34758-73 PMID: 26416449
  83. Vascular endothelial growth factor-C promotes alloimmunity by amplifying antigen-presenting cell maturation and lymphangiogenesis.
    Invest Ophthalmol Vis Sci. 2012 Mar 09;53(3):1244-50 PMID: 22281820
  84. Expression and function of semaphorin 3A and its receptors in human monocyte-derived macrophages.
    Hum Immunol. 2009 Apr;70(4):211-7 PMID: 19480842
  85. NG2 proteoglycan-dependent recruitment of tumor macrophages promotes pericyte-endothelial cell interactions required for brain tumor vascularization.
    Oncoimmunology. 2015 Jan 22;4(4):e1001204 PMID: 26137396
  86. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.
    Cancer Res. 2010 May 1;70(9):3526-36 PMID: 20406969
  87. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
    N Engl J Med. 2015 Jul 30;373(5):428-37 PMID: 26222558
  88. Anatomy of a discovery: m1 and m2 macrophages.
    Front Immunol. 2015 May 05;6:212 PMID: 25999950
  89. Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
    Int J Cancer. 2016 Jan 15;138(2):451-62 PMID: 26239999
  90. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer.
    Lung Cancer. 2005 May;48(2):223-31 PMID: 15829322
  91. Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models.
    Oncotarget. 2015 Apr 30;6(12):10563-76 PMID: 25868854
  92. Angiogenic effect of thymidine phosphorylase on macrophages in glioblastoma multiforme.
    J Neurosurg. 2001 Jul;95(1):89-95 PMID: 11455962
  93. Notch1 controls macrophage recruitment and Notch signaling is activated at sites of endothelial cell anastomosis during retinal angiogenesis in mice.
    Blood. 2011 Sep 22;118(12):3436-9 PMID: 21795743
  94. The Semaphorin 4D-Plexin-B1-RhoA signaling axis recruits pericytes and regulates vascular permeability through endothelial production of PDGF-B and ANGPTL4.
    Angiogenesis. 2014 Jan;17(1):261-74 PMID: 24114199
  95. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
    Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4470-5 PMID: 27044097
  96. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
    Clin Cancer Res. 2010 Jul 1;16(13):3420-30 PMID: 20570927
  97. Macrophages induce COX-2 expression in breast cancer cells: role of IL-1β autoamplification.
    Carcinogenesis. 2011 May;32(5):695-702 PMID: 21310944
  98. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.
    EMBO Mol Med. 2015 Dec 14;8(1):39-57 PMID: 26666269
  99. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.
    Clin Cancer Res. 2011 Sep 1;17(17):5668-73 PMID: 21788356
  100. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.
    Cell Rep. 2015 Apr 28;11(4):577-91 PMID: 25892230
  101. Definition of a serum marker panel for glioblastoma discrimination and identification of Interleukin 1β in the microglial secretome as a novel mediator of endothelial cell survival induced by C-reactive protein.
    J Proteomics. 2015 Oct 14;128:251-61 PMID: 26232108
  102. The pathogenic role of angiogenesis in rheumatoid arthritis.
    Angiogenesis. 2015 Oct;18(4):433-48 PMID: 26198292
  103. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression.
    J Immunol. 2006 Nov 15;177(10):7303-11 PMID: 17082649
  104. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas.
    Clin Cancer Res. 1999 May;5(5):1107-13 PMID: 10353745
  105. The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE₂ in murine macrophages.
    Int Immunopharmacol. 2010 Oct;10 (10 ):1220-8 PMID: 20637838
  106. Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment.
    Blood. 2010 Jun 17;115(24):5053-6 PMID: 20375314
  107. IL10-driven STAT3 signalling in senescent macrophages promotes pathological eye angiogenesis.
    Nat Commun. 2015 Aug 11;6:7847 PMID: 26260587
  108. RORC1 Regulates Tumor-Promoting "Emergency" Granulo-Monocytopoiesis.
    Cancer Cell. 2015 Aug 10;28(2):253-69 PMID: 26267538
  109. Macrophage diversity enhances tumor progression and metastasis.
    Cell. 2010 Apr 2;141(1):39-51 PMID: 20371344
  110. Serum YKL-40, a new prognostic biomarker in cancer patients?
    Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202 PMID: 16492905
  111. YKL-40 acts as an angiogenic factor to promote tumor angiogenesis.
    Front Physiol. 2013 May 28;4:122 PMID: 23755018
  112. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
    Invest Ophthalmol Vis Sci. 2013 May 03;54(5):3082-93 PMID: 23580490
  113. The role of microglia and macrophages in glioma maintenance and progression.
    Nat Neurosci. 2016 Jan;19(1):20-7 PMID: 26713745
  114. YKL-40-mediated interleukin 8 production may be closely associated with remodeling of bronchial smooth muscle cells.
    Am J Respir Crit Care Med. 2012 Aug 15;186(4):386; author reply 386-7 PMID: 22896594
  115. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients.
    J Immunother Cancer. 2015 Nov 17;3:54 PMID: 26579227
Article Info
Journal
Neuro-oncology
Abbr.
Neuro Oncol
ISSN
1523-5866
DOI
10.1093/neuonc/nox081
Published
2017-10-19
Pages
1435-1446
Language
English
Region
England
NLM ID
100887420
PMCID
PMC5737221
Subset
IM
External Links
PubMed source DOI: 10.1093/neuonc/nox081 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2